Feature Image

CBD Oil to be Center of Discussion at Upcoming International Epilepsy Congress

HempMeds® Mexico and its flagship product, Real Scientific Hemp Oil-X™ (RSHO-X™), will be an important part of the conversation surrounding the treatment of seizures at next week’s 32nd International Epilepsy Congress in Barcelona, Spain.

Scheduled for September 2-6, the International Epilepsy Congress gives attendees the unique opportunity to interact face to face with some of the field’s important researchers and reveal latest developments in our understanding of epilepsy. RSHO-X™’s efficacy in the treatment of epilepsy will be presented at the event by noted pediatric neurologist, Dr. Saul Garza.

Efficacy of CBD Oil

At the International Epilepsy Congress, Dr. Garza will outline his recent study using RSHO-X as a method of treatment for Lennox-Gastaut Syndrome (LGS). The study included 39 patients with Lennox-Gastaut syndrome, a severe form of pediatric epilepsy. In those 39 patients, an 84% average reduction in motor seizures were experienced; 53% of patients reported better than a 75% reduction in seizures; and 17% reported a complete elimination of all seizures over a 4-month period. No adverse side effects were reported among the patient population. Dr. Garza’s presentation will be at 1:30 p.m. on Sunday, September 3.

hempmeds-blog-image-what-is-cannabidiol-10-13-16-ver2

“We are thrilled that Dr. Garza was chosen to present his findings at the International Epilepsy Congress as this study shows our botanical CBD to provide the best available therapeutic intervention within this epilepsy patient population.  Given the advanced nature of these children’s conditions, it is pretty remarkable that 17% of the Lennox-Gastaut Syndrome patients experienced a total, 100% relief from their seizure episodes” said CEO of Medical Marijuana, Inc. Dr. Stuart Titus. “Studies like Dr. Garza’s help prove that the therapeutic benefits of botanically-oriented CBD are real and are helping fuel increased access to medical cannabis programs across the globe.”

RSHO-X™ in Mexico

First developed for the Mexican market, THC-free RSHO-X™ has played an important role in the progress of medical cannabis legalization in the country. RSHO-X™ was initially imported into Mexico for Graciela Elizalde Benavides. Diagnosed with Lennox-Gastaut syndrome, Grace was suffering up to 400 seizures daily. After her family took the Mexican government to court, RSHO-X™ was authorized as a treatment for Grace. This opened the door for more and more patients with a variety of medical conditions to access CBD oil and created a shift in the perception of medical cannabis in Mexico.

hempmeds-blog-image-10-12-16-ver2

CBD Oil in Spain and the European Union

Across the European Union, CBD oil products derived from hemp can be sold as dietary supplements. In the EU, hemp must contain no more than 0.2% THC per dry weight. If products meet EU criteria, then they can be sold throughout the European Union.

In Spain, this legality was verified in 2009 when the Court of Justice handed down a categorical ruling on Case C‑88/07 (Commission of the European Communities v Kingdom of Spain) on the free movement of goods and products classified as medicinal products and products lawfully produced or marketed as food supplements or dietary products in other EU member states.

Like in other markets in the EU and around the world, there is a growing desire for CBD oil products that is driving a cultural shift in the perception of cannabinoids and their therapeutic potential.

You can learn more about, hemp, CBD oil, and the medical marijuana industry on our education page.

  • August 30, 2017
  • Jeffrey Stamberger